Navigation Links
YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
Date:12/10/2009

Collaboration to Create Optimized Antibodies Produces First Candidates Which Selectively Target HER2 in Breast Cancer

MISSISSAUGA, ON, Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface receptors associated with cancer, uniquely optimized to produce efficacy with reduced toxicities. The first successfully designed and delivered products from the collaboration are a number of antibodies that bind to HER2/neu-over-expressing breast cancer cells while minimally binding to HER2 on normal cardiac cells. The lead candidate antibody for conjugation is in the final stages of selection from that number.

"This is a new generation of rationally designed antibodies that bind to HER2/neu on cancer cells to an extent similar to that seen with trastuzumab (Herceptin(R), Genentech/Roche) but are distinguished from trastuzumab by their minimal targeting of HER2 on cardiac cells, which is expected to result in reduced collateral cardiac toxicity," said David Allan, Chairman and CEO of YM BioSciences. "The improved specificity of these anti-HER2 antibodies makes them amenable to conjugation with highly potent toxins which would permit the selected IntelliMab anti-HER2/neu conjugate antibody to be an important competitor to Trastuzumab-DM1 (Genentech/Immunogen)."

"Subsequent to the soon-to-be-completed functional studies for this panel of antibodies, the optimal candidate will be entered into full development," added Mr. Allan. "This work was informed by published observations for our lead antibody, nimotuzumab, which is differentiated from its competitors by its remarkably diminished toxicity."

HER2 (also known as
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Biosciences Acquires Protein Forest
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
4. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
5. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
6. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
7. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
9. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
10. YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... , May 28, 2015 Natera, Inc., ... a study published in Ultrasound in Obstetrics ... polymorphism (SNP)-based non-invasive prenatal test (NIPT) can identify ... A study based upon data ... pregnancies occur in about 1 in 1,000 pregnancies, ...
(Date:5/28/2015)... N.J. , May 28, 2015  PDS ... a cancer immunotherapy treatment targeting HPV-16, has generated ... Currently, pre-cervical cancer is treated by ... a simple and effective non-surgical alternative. Results show ... mechanisms (T-cells) to recognize, target, and kill precancerous ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
Breaking Biology Technology:Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2GenVec To Present At The Jefferies Healthcare Conference 2
... , CARLISLE, Mass., Aug. 5 ... launch of a fully integrated microarray solution platform. ... biochips and advanced microarray instrument systems, in collaboration ... and instrumentation software, now offers a platform that ...
... , CHICAGO, Aug. 5 Advanced ... it will host a conference call and webcast discussing the Company,s ... a.m. (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, ... present an update on the Company. A press release reporting the ...
... Framework Reaffirmed , Shire plc (LSE: SHP, NASDAQ: SHPGY ) the global specialty,biopharmaceutical company, announces results for the ... ... Q2 2009(1), Product sales ... -21%, Product sales (excluding ADDERALL XR) $491 million ...
Cached Biology Technology:CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 2CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform 3Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 2Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 3Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 4Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 5Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 6Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 7Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 8Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 9Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 10Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 11Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 12Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 13Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 14Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 15Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 16Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 17Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 18Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 19Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 20Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 21Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 22Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 23Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 24Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 25Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 26Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 27Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 28Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 29Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 30Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 31Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 32Shire plc: Core Portfolio of Products Delivers 20% Sales Growth 33
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/8/2015)... JOSE, Calif. , May 8, 2015 Synaptics ... interface solutions, today announced that members of the executive management ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Waterfront Hotel in Boston, MA ... May 27, 2015 Time: 2:45pm ET Location: The New York ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Ky. The University of Louisville today announced that ... into a license and research collaboration agreement with Novartis ... the potential to help transplant patients avoid taking anti-rejection ... for treatment of other diseases. The University ...
... Boston University School of Medicine (BUSM) suggests that epigenetics may ... relapse of cancer. The findings are published online in Volume ... The term epigenetics refers to the external modifications ... do not change the DNA sequence, but instead, they affect ...
... MA New insights into how human cytomegalovirus ... with infection spreads from pregnant mother to fetus ... translational researchers an exciting new avenue for investigation ... interventions. Using next generation sequencing and population genetic ...
Cached Biology News:University of Louisville researchers sign global licensing agreement 2University of Louisville researchers sign global licensing agreement 3BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy 2Research points to potential window for treating CMV and preventing mother-to-child transmission 2Research points to potential window for treating CMV and preventing mother-to-child transmission 3
... Designed to meet the ... this animal component-free medium supports ... high cell densities, while maintaining ... recombinant protein production using the ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z36,327-8) ...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: